+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 89 Actively Recruiting clinical trials

B

Actively Recruiting

Researchers aim to improve understanding and treatment of brain metastases from solid tumors, which currently have limited systemic treatment options. This study focuses on patients with newly diagnosed non-CNS metastatic solid tumors who are at high risk of developing central nervous system CNS metastases. By gathering detailed clinical and biological information, including analyses of circulating tumor DNA ctDNA from cerebrospinal fluid CSF samples, the study seeks to identify new therapeutic targets and develop innovative treatment strategies. The study is organized into three time periods before the first CNS event Part A, at the first CNS diagnosis Part B, and after the first CNS event Part C. Participants will undergo scheduled collections of plasma, serum, CSF samples, and non-CNS metastatic tumor tissue as applicable, along with brain MRI scans at specific intervals depending on their part in the study. Sample collections and imaging are scheduled annually, every few months, or as clinically indicated, aligned with the participants cancer type and study period. Participants will have regular assessments including imaging and biological sample collections to monitor disease progression and tumor biology. Researchers will analyze the epidemiology and biology of CNS metastases over approximately eight years. Study procedures include lumbar punctures for CSF collection, brain MRIs, and collection of tumor tissue when possible. Participants safety and life expectancy are considered, and follow-up will continue throughout the study duration to support data collection and understanding of CNS metastases.

Age: 18Years +All GendersPhase Not Applicable
17 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of L606 in people with pulmonary hypertension caused by interstitial lung disease PH-ILD, WHO Group 3. The study focuses on whether L606 helps participants walk further in six minutes, using the six-minute walk test as a main measure. It also examines how long it takes for PH-ILD to worsen under treatment, alongside close monitoring for any side effects. Participants are randomly assigned to receive either L606, a liposomal form of treprostinil delivered by inhalation with a nebulizer, or a placebo that looks like L606 but contains no active medicine. After the initial blinded phase, participants may join an open-label extension where all receive L606. The study uses a parallel design with quadruple masking to compare outcomes between groups. During the trial, participants will attend visits to assess walking distance at multiple time points, monitor lung health, and watch for side effects. Key measurements include changes in six-minute walk distance at 16 and 24 weeks and the time until worsening events like hospitalization or lung transplant. The study is expected to continue until 2031, with safety and efficacy carefully tracked throughout.

Age: 18Years - 80YearsAll GendersPhase 3
44 locations
P

Actively Recruiting

Researchers are evaluating AZD8205, a new antibody drug conjugate, as a possible treatment for advanced or metastatic solid tumors including breast cancer, biliary tract carcinoma, ovarian cancer, endometrial cancer, and squamous non-small cell lung cancer. This Phase IIIa multi-center, open-label study aims to assess AZD8205 alone or combined with other anti-cancer agents to determine safety, tolerability, dosing, and anti-tumor activity. The study includes multiple sub-studies focusing on different drug combinations and tumor types. Participants may receive AZD8205 as monotherapy or in combination with rilvegostomig, saruparib, and AZD9574. The study has dose escalation phases to identify the recommended phase 2 dose and expansion phases to evaluate anti-tumor effects in selected solid tumors. Some combinations may involve triplet therapies depending on emerging safety data. Treatments will be given according to protocol schedules within each sub-study. Throughout the study, participants will undergo regular monitoring for adverse events, lab tests, ECGs, vital signs, and pharmacokinetic assessments for up to two years. Researchers will measure outcomes such as response rates, duration of response, progression-free survival, overall survival, and immunogenicity. Safety evaluations continue from informed consent to 30 days after the last dose. The study is randomized and open-label, with ongoing assessments during treatment and follow-up periods.

Age: 18Years +All GendersPhase 1Phase 2
67 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of new combinations of treatments, including novel drugs and standard therapies, for patients with advanced or metastatic non-small cell lung cancer NSCLC. This multicenter, open-label study focuses on participants with stage IV NSCLC, specifically assessing combinations involving rilvegostomig with platinum-based chemotherapy and with or without ramucirumab. The study includes a sub-study with safety and dose expansion phases to identify the recommended dose and assess treatment activity. Participants with squamous and non-squamous NSCLC will receive intravenous infusions of rilvegostomig combined with standard chemotherapy drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel. Some participants will also receive ramucirumab as part of their treatment. The sub-study consists of a Part A safety run-in to evaluate dose levels and a Part B expansion phase to further study the treatments. Participants are randomized into different treatment arms depending on their cancer histology. During the study, participants will undergo monitoring for adverse events, dose-limiting toxicities, and tumor response over approximately 46 months. Assessments include measuring objective response, duration and time to response, disease control, progression-free survival, overall survival, and various blood drug concentration parameters. Tumor tissue samples are required for evaluation, and safety and tolerability are closely monitored throughout the treatment period.

Age: 18Years +All GendersPhase 1Phase 2
103 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness and safety of zanidatamab combined with a physicians choice of chemotherapy compared to trastuzumab combined with chemotherapy in treating adults with metastatic HER2-positive breast cancer who have either progressed on or cannot tolerate previous trastuzumab deruxtecan T-DXd treatment. Zanidatamab has shown promising results against various HER2-positive advanced tumors, including metastatic breast cancer, and may serve as a potential treatment option for these patients. The study also investigates patient-reported tolerability and physical functioning, as well as the pharmacokinetics and immune response to zanidatamab with chemotherapy. Participants will be randomly assigned to receive either zanidatamab or trastuzumab, each given by intravenous infusion alongside one of several chemotherapy options chosen by the physician eribulin, vinorelbine, gemcitabine, or capecitabine the latter is taken orally. Treatment will be administered according to the assigned group, and the study is open-label and multicenter, designed to compare these two treatment combinations in this patient population. During the study, participants will undergo regular assessments to monitor disease progression using imaging criteria RECIST version 1.1, evaluate survival, treatment response, and duration of response. Safety and side effects will be tracked through adverse event reporting and patient questionnaires on symptoms and physical function. Blood samples will be collected to study drug levels and immune reactions. Participants will be followed until disease progression, death, or for up to approximately 44 months for key outcomes, with overall survival monitored for up to about 80 months.

Age: 18Years +All GendersPhase 3
166 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.

Age: 18Years +All GendersPhase 2
129 locations
R

Actively Recruiting

The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.

Age: 18Years +All GendersPhase 3
251 locations

1-10 of 89

1